Pharma Player Enters Rs 648 Crore Antiseptic Segment with Wokadine Acquisition

On Wednesday, Corona Remedies' share price closed at Rs 1,546.9, compared to the previous close of Rs 1,556.15, declining by 0.59 per cent. The stock remained in focus after the company announced the acquisition of Wokadine to strengthen its presence in the healthcare segment.

Acquisition of Wokadine expands Corona Remedies’ presence in Rs 648 crore antiseptic market

Corona Remedies has acquired Wokadine from Dr. Reddy’s Laboratories Ltd., marking its fifth acquisition to date. The transaction became effective on March 30, 2026.

With this acquisition, Corona Remedies has entered the Rs 648 crore Povidone Iodine market, adding an established antiseptic brand with a long presence in India. The acquired product holds a strong position in its category and is widely used across multiple medical settings.

The company expects this move to strengthen its presence in key therapeutic segments and improve its reach among doctors, including surgeons, ENT specialists, general physicians and gynaecologists. The product portfolio includes multiple variants designed for different treatment needs, supporting wider clinical use. Corona Remedies plans to leverage its existing sales and distribution network to expand the product’s availability across metro, urban and rural markets. The acquisition will be funded through internal accruals and available cash resources.

Corona Remedies Management Commentary 

Commenting on the development, Tejas Kothari, Vice President – Corporate Strategy & Business Development, said the company continues to assess organic and inorganic growth opportunities, focusing on strengthening brands by leveraging its extensive reach, strong trust among doctors and the medical fraternity, a pan-India distribution network, and a dedicated sales and marketing team. He added that the acquisition is expected to enhance and strengthen the existing product portfolio, deepen market penetration and accelerate the brand’s growth.

About Corona Remedies

Corona Remedies Limited is an Indian pharmaceutical company focused on developing and marketing branded formulations across multiple therapeutic areas. The company has a presence in segments such as women’s healthcare, cardiology, pain management, anti-infectives and gastroenterology. It operates with a strong domestic distribution network and a growing portfolio of speciality products, catering to doctors and healthcare professionals across India.

Share your thoughts on Corona Remedies’ acquisition of Wokadine in the comments below.
Disclaimer: The article is for informational purposes only and not investment advice.